News

Home/News

Breaking News for GIST Patients – Avapritinib Approved!

Blueprint Medicines announced that the FDA has approved AYVAKIT™ (avapritinib) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.

By |2020-01-10T16:06:14-05:00January 9th, 2020|News|

First LRG GIST Mentor Training Takes Place in Wayne, NJ

An LRG GIST Mentor helps patients and their caregivers through their GIST journey – from receiving a diagnosis to navigating different resources of information, support, treatment options, side effects, etc.

By |2019-12-18T11:41:28-05:00December 18th, 2019|Advocacy, News, Newsletter|

Global Representative Spotlight – Amelia Yeo

I was a piano teacher and performing pianist for the past 13 years but stopped work completely this year so I could spend more time with Andrew and see to his needs. We were so lost in the beginning because we did not know what to expect, due to the relative rarity of GISTs.

By |2019-12-18T10:46:04-05:00December 18th, 2019|News, Newsletter, Patient Support|

NORD Hosts Rare Disease Summit

The National Organization for Rare Disorders (NORD) held a Rare Disease Summit in Washington, D.C. October 20019, hosting several thousand people comprised of patients, advocates, non-profit employees, health providers, IT developers, pharmaceutical staff, physicians and researchers, and representatives from government entities.

By |2019-12-18T11:06:15-05:00December 18th, 2019|Advocacy, Conferences, News, Newsletter|

Night to Fight Cancer Lights Up the Night for #GISTresearch

The 16th annual Night to Fight Cancer (NTFC) took place on October 24th, 2019 at the Midtown Loft and Terrace in New York City. This annual event benefits The Life Raft Group’s research programs.

By |2019-12-19T11:21:57-05:00December 18th, 2019|Fundraising, News, Newsletter|